NewsRx

Search our medical news database

Sirtex

Officials from Sirtex provide details of new developments

Published in Healthcare Mergers, Acquisitions and Ventures Week, April 21st, 2007

Officials from Sirtex provide details of new developments.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Sirtex.

Report 1: New data on Sirtex's SIR-Spheres microspheres were presented in a poster session reporting the findings of a new retrospective analysis evaluating liver tolerance to repeated doses of radiation from SIR-Spheres microspheres (90Y-microspheres).

Sirtex's SIR-Spheres microspheres are the only U.S. Food & Drug Administration-approved microsphere therapy for liver tumors that originate in the colon or rectum.

The team analyzed the data...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook